Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.41 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453067 | 0.77 | IDO1 (0.65) | IDO1SMN1; SMN2LMNACYP1A2MAPT | |
| SCHEMBL1948725 | 0.71 | IDO1 (1.00) | IDO1CYP3A4 | |
| SCHEMBL8986487 | 0.68 | DCUN1D1 (0.49) | IDO1SMN1; SMN2LMNACYP1A2MAPT | |
| SCHEMBL22074301 | 0.67 | ESR2 (0.53) | SMN1; SMN2LMNACYP1A2MAPTCYP2C9 | |
| SCHEMBL28029281 | 0.67 | SMN1; SMN2 (0.61) | IDO1SMN1; SMN2LMNACYP1A2MAPT | |
| SCHEMBL57748 | 0.65 | SMN1; SMN2 (0.57) | IDO1SMN1; SMN2LMNACYP1A2MAPT | |
| SCHEMBL6265094 | 0.65 | MAPT (0.49) | SMN1; SMN2LMNACYP1A2MAPTCYP2C9 | |
| SCHEMBL14198211 | 0.64 | MAPT (0.51) | IDO1SMN1; SMN2LMNACYP1A2MAPT | |
| SCHEMBL7234362 | 0.64 | CYP1A2 (0.55) | SMN1; SMN2LMNACYP1A2MAPTCYP2C9 | |
| SCHEMBL10356483 | 0.63 | ALDH1A1 (0.56) | IDO1SMN1; SMN2LMNAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936857-B | Reagents and methods for predicting response to therapy | 艾比克斯治疗私人有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-112805267-B | Carboxamide and sulfonamide derivatives as TEAD modulators | 豪夫迈·罗氏有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117440826-A | Administration of treatment with anti-CD 20/anti-CD 3 bispecific antibodies | 基因泰克公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-111213059-B | Diagnostic and therapeutic methods for cancer | 豪夫迈·罗氏有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117355332-A | Methods of treating CD20 positive proliferative disorders with Mo Suni tobulizumab and velopmental bulizumab | 基因泰克公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117098537-A | Combination therapy for cancer treatment | 医睿世康药业研发公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-117083283-A | Combination therapy for cancer treatment | 医睿世康药业研发公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-116917317-A | Administration for treatment with anti-CD 20/anti-CD 3 bispecific antibody and anti-CD 79B antibody drug conjugates | 基因泰克公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116406291-A | Administration of treatment with anti-FCRH 5/anti-CD 3 bispecific antibodies | 基因泰克公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116327953-A | Methods of treating locally advanced or metastatic breast cancer using PD-1 axis binding antagonists and taxanes | 豪夫迈·罗氏有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-109476748-B | Methods for treatment and diagnosis of cancer | 豪夫迈·罗氏有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116003409-A | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-114555116-A | Administration for anti-TIGIT and anti-PD-L1 antagonist antibody therapy | 豪夫迈·罗氏有限公司 | 2022-05-27 | — | — | CN | disclosed |